# Tiago Torres

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tiago-torres/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,671 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 42 |
| i10-index | 139 |
| Last Known Institution | Universidade do Porto |
| OpenAlex ID | https://openalex.org/A5077025645 |
| ORCID iD | 0000-0003-0404-0870 |
| Works | 349 |

## Researcher papers

- [Update on Atopic Dermatitis](https://scholariq.org/papers/update-on-atopic-dermatitis/)
- [Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study](https://scholariq.org/papers/factors-associated-with-adverse-covid-19-outcomes-in-patients-with-psoriasis/)
- [JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors](https://scholariq.org/papers/jak-inhibitors-for-treatment-of-psoriasis-focus-on-selective-tyk2-inhibitors/)
- [Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib](https://scholariq.org/papers/selective-jak1-inhibitors-for-the-treatment-of-atopic-dermatitis-focus-on/)
- [Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study](https://scholariq.org/papers/drug-survival-of-il-12-23-il-17-and-il-23-inhibitors-for-psoriasis-treatment-a/)
- [Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19](https://scholariq.org/papers/association-between-tumor-necrosis-factor-inhibitors-and-the-risk-of/)
- [Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects](https://scholariq.org/papers/palmoplantar-psoriasis-and-palmoplantar-pustulosis-current-treatment-and-future/)
- [Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis](https://scholariq.org/papers/apremilast-a-novel-oral-treatment-for-psoriasis-and-psoriatic-arthritis/)
- [Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change](https://scholariq.org/papers/risk-of-tuberculosis-reactivation-with-interleukin-il-17-and-il-23-inhibitors-in/)
- [The Protective Role of HLA-DRB1<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"/>13 in Autoimmune Diseases](https://scholariq.org/papers/the-protective-role-of-hla-drb1-mml-math-xmlns-mml-http-www-w3-org-1998-math/)
- [The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal](https://scholariq.org/papers/the-apolo-study-a-cross-sectional-analysis-of-disease-characteristics-and/)
- [Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-AD](https://scholariq.org/papers/multidimensional-burden-of-moderate-to-severe-atopic-dermatitis-in-adolescent/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

## Researcher university

- [Universidade do Porto](https://scholariq.org/institutions/universidade-do-porto/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.